Correlation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
Correlation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal® NASH bundle test in a recently completed clinical trial.
This trial, FALCON 1, was a Phase IIb multicenter, double-blind study of three pegbelfermin doses in patients with stage III nonalcoholic steatohepatitis (NASH).
The primary endpoint of this and currently all NASH late-stage clinical trials consisted of liver biopsy histological staging. But, due to the issues inherent in the procedure and method, the ultimate ambition in the field is to replace biopsy with more noninvasive tests (NITs).
Learn about:
- Use of several NITs, including SomaSignal tests, their performance, and their relationship to the primary endpoint in the study
- Pharmacodynamics of drug response as measured by NITs
- Correlations of biomarkers covering all mechanistic features of NASH with each other and with biopsy-related endpoints
- Within-patient concordance of response and nonresponse to drug as measured by NITs and biopsy parameters
Anne Minnich, PhD
Consultant
Immunology, Cardiovascular, Fibrosis & Neuroscience Biomarkers
Translational Medicine
Bristol Myers Squibb
Anne Minnich is a biomarker scientist currently specializing in liver and lung fibrosis within clinical development at Bristol Myers Squibb. She received her doctorate in nutritional biochemistry from Cornell University, followed by a postdoctoral fellowship in molecular biology of lipoprotein metabolism at Boston University. She then conducted research on the clinical genetics of cardiovascular disease at the Clinical Research Institute of Montreal. Since then, she has spent over 20 years in the pharmaceutical industry at Sanofi and Bristol Myers Squibb in research and development in the areas of cardiovascular disease, immunology, and inflammation. Her focus for the past decade has been on biomarkers and fibrosis, designing and implementing biomarker strategies for early and late-stage clinical trials in immunology- and fibrosis-related diseases, including pulmonary fibrosis and NASH.
Correlation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
A presentation by Anne Minnich, PhD
More webinars
WebinarHarnessing AI and proteomics for glioblastoma
The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.
WebinarMapping the human mucosal immune response to respiratory viruses
Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.
WebinarAccelerating precision medicine of cancer with SomaScan® proteomics
Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.